PKCη was upregulated in samples from patients with CML with BCR-ABL-independent imatinib resistance or CML stem cells, leading to sustained RAF/MEK/ERK signaling following imatinib treatment. Here, MAP2K7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.